EyeGate Pharma Initiates Phase I Study of EGP-437 in Patients With Non … – PipelineReview.com (press release)
EyeGate Pharma Initiates Phase I Study of EGP-437 in Patients With Non …PipelineReview.com (press release)"We hope that this approach will provide more controlled local delivery of a corticosteroid through the episcleral/conjunctival plexus and …
